Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6557844 | 0.98 | CYP2C19 (0.46) | CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL28017411 | 0.86 | PTPN5 (0.44) | CYP2C19EPHX1 | |
| SCHEMBL7400131 | 0.85 | PREP (0.43) | CYP2D6LMNAMAPK1GABBR2GABBR1 | |
| SCHEMBL3053473 | 0.85 | GABBR2 (0.48) | CYP2C19CYP2D6GABBR2GABBR1PREP | |
| SCHEMBL19817286 | 0.85 | GABBR2 (0.48) | CYP2C19CYP2D6GABBR2GABBR1PREP | |
| SCHEMBL7514729 | 0.82 | PREP (0.43) | CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL28555786 | 0.81 | PREP (0.44) | CYP2C19CYP2D6GABBR2GABBR1PREP | |
| SCHEMBL27248171 | 0.81 | EPHX1 (0.38) | CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL7553283 | 0.81 | PREP (0.46) | CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2 | |
| SCHEMBL18248497 | 0.78 | PREP (0.42) | CYP2C19CYP1A2CYP2D6PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
| EP-4326270-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | Apollomics Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022226168-A1 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | APOLLOMICS INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-2943508-A2 | COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES | F. Hoffmann-La Roche AG (CH) | 2015-11-18 | — | — | EP | disclosed |
| EP-2912021-A1 | AGGRECANASE INHIBITORS | Eli Lilly and Company (US) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014108484-A2 | COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014066151-A1 | AGGRECANASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007107329-A1 | TUMOR THERAPY WITH AN ANTIBODY FOR VASCULAR ENDOTHELIAL GROETH FACTOR AND AN ANTIBODY FOR HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR TYPE 2 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-0305270-A1 | Imidazolidines substituted by a hydroxymethyl and a substituted phenyl radical, process for their preparation, their use as medicines, pharmaceutical compositions containing them and an intermediate for their preparation | ROUSSEL-UCLAF (FR) | 1989-03-01 | — | — | EP | disclosed |
| EP-0143123-A2 | Industrial products useful as intermediates in the preparation of 4-hydroxy-3 quinoleine carboxamide derivatives substituted at position 2, and the preparation of these intermediates | ROUSSEL-UCLAF (FR) | 1985-06-05 | — | — | EP | disclosed |
| EP-0141713-A1 | Process for preparation of 2-substituted quinoline-3- carboxamides | ROUSSEL-UCLAF (FR) | 1985-05-15 | — | — | EP | disclosed |